Quarterly report pursuant to Section 13 or 15(d)

Collaboration and Research Arrangements - Collaboration Agreement (Details)

v3.20.1
Collaboration and Research Arrangements - Collaboration Agreement (Details) - USD ($)
 1 Months Ended 3 Months Ended
Dec. 17, 2019
Jan. 08, 2018
Nov. 30, 2019
Jan. 31, 2018
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Deferred revenue         $ 27,476,000   $ 28,378,000
Deferred revenue, net of current portion         20,681,000   22,639,000
GBT              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Deferred revenue         19,275,000   20,000,000
GBT | Collaboration Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Initial period of research term 3 years            
Additional extension period for research term upon mutual agreement 1 year            
Upfront payment receivable $ 20,000,000            
Reimbursements receivable of full-time employee and out-of-pocket costs and expenses $ 40,000,000            
Agreement termination, prior written notice if notice delivered during the research term 9 months            
Agreement termination, prior written notice if notice delivered after the expiration or termination of the research term 90 days            
Total transaction price $ 60,000,000       60,000,000    
Upfront non-refundable and non-creditable payment 20,000,000            
Reimbursable costs $ 40,000,000            
Change in total transaction price         0    
Revenue recognized         2,200,000    
Deferred revenue         19,300,000    
Deferred revenue, short-term         5,400,000    
Deferred revenue, net of current portion         13,900,000    
GBT | Collaboration Agreement | Maximum [Member]              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Period of extension of initial research term 2 years            
Receivable from option exercise, development, regulatory, commercialization and sales-based milestones per product candidate and product resulting $ 315,000,000            
Incyte              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Revenue recognized         200,000 $ 500,000  
Deferred revenue         8,201,000   $ 8,378,000
Deferred revenue, short-term         1,400,000    
Deferred revenue, net of current portion         6,800,000    
Incyte | Collaboration Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Total transaction price   $ 12,300,000 $ 12,800,000   12,800,000    
Upfront non-refundable and non-creditable payment         2,500,000    
Up-front consideration       $ 10,000,000      
Up-front consideration, cash       2,500,000      
Up-front consideration, pre-paid research funding       $ 7,500,000      
Prepaid research amount         7,500,000    
Premium paid on equity investment         2,300,000    
Collaboration agreement additional consideration incurred         $ 500,000